Head-to-head dispatch
Peter MD vs Rylo Health
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
A physician-prescribed telehealth brand pairing GLP-1 tirzepatide and compounded semaglutide+B12 with TRT, sermorelin, NAD+, hair-loss and ED care on one account — tirzepatide from $249/mo, semaglutide+B12 from $149/mo.
Marked down on: Tirzepatide steps up after month one — $149 for the first month, then $249/mo billed quarterly
Desk Score
Texas-prescriber telehealth selling compounded semaglutide and tirzepatide alongside a peptide line, naming both its medical group and its dispensing pharmacy.
Marked down on: Headline $100 and $160 rates are limited to the first 20 patients; standard rates are $149 and $249
Peter MD takes this head-to-head with the higher Desk Score, 80/100 (B−) against 76/100 (C) for Rylo Health. Rylo Health still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Peter MD
80/100
B−
Rylo Health
76/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Peter MD | Rylo Health |
|---|---|---|
| Semaglutide | $149/mo (GLP1+B12, compounded, first-time tier; $139/mo returning-patient tier) | $149/mo (promotional rate, compounded) |
| Tirzepatide | $249/mo (60mg, billed quarterly; $149 first month) | $249/mo (compounded) |
| Coverage | Most states (restrictions vary by treatment — excludes several, incl. AL, ID) | All 50 states |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes. | Shoppers who want the pharmacy and medical group named before they buy. |
| Desk Score | 80/100B− | 76/100C |
The verdict
Desk pick — Peter MDPeter MD takes this head-to-head with the higher Desk Score, 80/100 (B−) against 76/100 (C) for Rylo Health. Rylo Health still holds its ground where its strengths line up with yours.
Choose Peter MD if…
Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes.
$149/mo (GLP1+B12, compounded, first-time tier; $139/mo returning-patient tier) sema · $249/mo (60mg, billed quarterly; $149 first month) tirz · Most states (restrictions vary by treatment — excludes several, incl. AL, ID)
Choose Rylo Health if…
Shoppers who want the pharmacy and medical group named before they buy.
$149/mo (promotional rate, compounded) sema · $249/mo (compounded) tirz · All 50 states
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Peter MD · Rylo Health.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Peter MD vs CoreAge Rx
- Rylo Health vs Vaylen
- Peter MD vs Strut Health
- Rylo Health vs Ondra Health
- Peter MD vs Invigor Medical
- Rylo Health vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.